US Stock MarketDetailed Quotes
CVKD Cadrenal Therapeutics
- 14.150
- +0.440+3.21%
Close Nov 27 16:00 ET
- 14.150
- 0.0000.00%
Post 20:01 ET
23.47MMarket Cap-2296P/E (TTM)
14.430High13.189Low33.03KVolume14.430Open13.710Pre Close456.42KTurnover3.02%Turnover RatioLossP/E (Static)1.66MShares32.55052wk High6.88P/B15.48MFloat Cap5.40052wk Low--Dividend TTM1.09MShs Float101.250Historical High--Div YieldTTM9.05%Amplitude5.400Historical Low13.818Avg Price1Lot Size
About Cadrenal Therapeutics Company
Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focused on developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang Pham and Matthew Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.
Company Profile
SymbolCVKD
Company NameCadrenal Therapeutics
Listing DateJan 20, 2023
Issue Price5.00
Founded2022
CEOMr. Quang X. Pham
MarketNASDAQ
Employees4
Fiscal Year Ends12-31
Address822 A1A North,Suite 306
CityPonte Vedra Beach
ProvinceFlorida
CountryUnited States of America
Zip Code32082
Phone1-904-300-0701
Websitehttp://www.cadrenal.com
Company Executives
- Name
- Position
- Salary
- Quang X. Pham
- Chairman of the Board and Chief Executive Officer
- 967.00K
- Matthew K. Szot
- Chief Financial Officer and Principal Accounting Officer
- 844.89K
- Dr. Douglas W. Losordo, M.D.
- Chief Medical Officer
- 528.69K
- Jeffrey Cole
- Chief Operating Officer
- --
- Steven Zelenkofske
- Independent Director
- 35.00K
- Robert Lisicki
- Independent Director
- 74.50K
- John Raymond Murphy
- Independent Director
- 50.00K
- Dr. Glynn Wilson,PhD
- Independent Director
- 35.00K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data